# A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate

> **NCT01059773** · PHASE4 · COMPLETED · sponsor: **Janssen-Cilag International NV** · enrollment: 490 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Ustekinumab
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT01059773
- **Lead sponsor:** Janssen-Cilag International NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-11
- **Final completion:** 2011-08
- **Target enrollment:** 490 (ACTUAL)
- **Last updated:** 2014-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01059773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01059773, "A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01059773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*